Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Up 46.2% in January

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 658,100 shares, a growth of 46.2% from the December 31st total of 450,000 shares. Currently, 2.6% of the shares of the stock are short sold. Based on an average daily volume of 276,000 shares, the days-to-cover ratio is currently 2.4 days.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. R Squared Ltd acquired a new position in Vistagen Therapeutics during the 4th quarter worth approximately $25,000. Jane Street Group LLC bought a new position in shares of Vistagen Therapeutics during the third quarter valued at about $59,000. Virtu Financial LLC boosted its stake in shares of Vistagen Therapeutics by 30.5% in the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock worth $61,000 after buying an additional 4,722 shares during the last quarter. HighTower Advisors LLC purchased a new stake in shares of Vistagen Therapeutics during the third quarter valued at approximately $64,000. Finally, Valence8 US LP bought a new position in Vistagen Therapeutics in the 3rd quarter valued at $103,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

Vistagen Therapeutics Trading Up 2.8 %

VTGN stock opened at $2.94 on Friday. The company has a 50 day simple moving average of $2.77 and a 200 day simple moving average of $3.06. Vistagen Therapeutics has a 1 year low of $2.22 and a 1 year high of $5.74.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). Vistagen Therapeutics had a negative net margin of 4,521.71% and a negative return on equity of 36.35%. The firm had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.34 million. During the same period in the prior year, the company earned ($0.66) EPS. Research analysts forecast that Vistagen Therapeutics will post -1.85 EPS for the current fiscal year.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.